Loading...
Loncar Cancer Immunotherapy ETF
CNCR•NASDAQ
Financial ServicesAsset Management
$9.16
$0.30(3.39%)
Loncar Cancer Immunotherapy ETF (CNCR) Stock Overview
Explore Loncar Cancer Immunotherapy ETF’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CNCRStats details for CNCR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CNCRAnalyst Recommendations details for CNCR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Headquarters
DE
Founded
2015